Vetter’s V-OVS® next tamper-evident syringe closure system to knock on the door of the healthcare sector

Introduction

Vetter, a well-known Contract Development and Manufacturing Organisation (CDMO), with a position of expertize of aseptic end-to-end process of injectable drugs, mainly for critical biologics such as vaccines and antibodies. Through this robust delivery, the company seals the deal with early development and marketing suppliers. Straight from Germany, the company delivers its commendable drug delivery systems, exclusive services and technology package with analytical help, device installation and valuable/effective solutions on order/request. The company has also raised standards for healthcare packaging.

Announcement

Vetter has recently wrapped up the numerous important steps required for their ongoing development for smooth FDA approvals for the same, and is planning to soon launch V-OVS®. The company is behaving responsibly since the extended market feedback, and the introduction of a well-structured new closure system is fundamental. The updates to be noted are the innovative/easy functionality, fascinating design and natural handling that will be suitable for the syringe formats.

These updates and the latest news of V-OVS® arrival were revealed at the PharmaPack 2025 shed new hope to the industries carrying a similar interest to advocate Vetter’s innovation in their operation. Since the revelation, the closure registered various steps regarding marketing readiness for long-term goals.

New Year, New advancement

These new advancements harnessing with updates and spotting many improvement areas, will advance the usability and protection of the upcoming V-OVS®. V-OVS® will further serve best to the applications throughout the extensive markets like aesthetic injectables, biologics, diluents and ophthalmology.

Just after fixing the key areas of the development process, the company took its valuable time to confirm the design of V-OVS® next and unlocked new pathways for industrialisation. Considering these whole updates, changes and innovations as part of the process, Vetter will serve its impeccable first-hand syringe glass suppliers along with NFHU materials to brief testing and contribute to execution in the vast syringe formats.

Senior Vice President, Global Sales Organisation at Vetter, Lars Hahn, said, “Our first biopharma customers' positive feedback is exciting, and so we are moving ahead to receive such positive feedback from glass suppliers too. With the successful conversations with various value chain partners, alongside continuous empowering responses, bolsters our confidence in this upcoming launch.”

Additional

Vetter also succeeded in taking two more fundamental verification steps all on its own, as the major Functional Study, and first Human Factors study (2025), a robust second Human Factors study confirmed positive, reliable results, flaunting the potential of V-OVS® next.